Wouldn’t you want the most reliable data on the market for your clinical studies?
Cytognomix can offer novel array CGH designs with expanded probe sequence repertoire and significantly improved reproducibility than other available platforms. This technology enables higher density arrays to be produced which provide higher granularity and more consistent copy number calls. Arrays can be targeted for specific genomic regions to refine results from lower resolution genome-wide studies or developed for genome-wide applications.
A subscription to our MutationForecaster system provides genome browser access to our genome-wide custom probe designs through the cytogenetic Visual Analytics Decision Support Tool. This tool displays the locations of oligonucleotide products used in microarray design.
Please contact us regarding these designs and protocols.
We have published a paper describing how ab initio sc technology improves microarray reproducibility: Expanding probe repertoire and improving reproducibility in human genomic hybridization. Stephanie N. Dorman; Ben C. Shirley; Joan H. M. Knoll; Peter K. Rogan. Nucleic Acids Research 2013; doi: 10.1093/nar/gkt048
- February 27, 2017. CytoGnomix finalizes contract with Government of Canada
- Jan. 28, 2017. New version of F1000Research paper on chemotherapy response in breast cancer
- January 25, 2017. Comment from the Transforming Genetic Medicine Initiative Blog
- Jan. 23, 2017. Automated interpretation of digital pathology images is currently at an embryonic stage of development